1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Postpartum Depression – Pipeline Insight, 2020

Postpartum Depression – Pipeline Insight, 2020

  • September 2020
  • 55 pages
  • ID: 5968546
  • Format: PDF
  • Delve Insight


Table of Contents

“Postpartum Depression – Pipeline Insight, 2020,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Postpartum Depression Understanding

Postpartum Depression: Overview
The birth of a baby can trigger a jumble of powerful emotions, from excitement and joy to fear and anxiety. Most new moms experience postpartum "baby blues" after childbirth, which commonly include mood swings, crying spells, anxiety and difficulty sleeping. Baby blues typically begin within the first two to three days after delivery, and may last for up to two weeks. But some new moms experience a more severe, long-lasting form of depression known as postpartum depression. Rarely, an extreme mood disorder called postpartum psychosis also may develop after childbirth. Postpartum depression isn’t a character flaw or a weakness. Sometimes it’s simply a complication of giving birth.

Signs and symptoms of depression after childbirth vary, and they can range from mild to severe.

• Baby blues symptoms
1. Mood swings
2. Anxiety
3. Sadness
4. Irritability
5. Feeling overwhelmed
6. Crying
7. Reduced concentration
8. Appetite problems
9. Trouble sleeping
• Postpartum depression signs and symptoms may include:
1. Depressed mood or severe mood swings
2. Excessive crying
3. Difficulty bonding with your baby
4. Withdrawing from family and friends
5. Loss of appetite or eating much more than usual
6. Inability to sleep (insomnia) or sleeping too much
7. Overwhelming fatigue or loss of energy
8. Reduced interest and pleasure in activities you used to enjoy
9. Intense irritability and anger
10. Fear that you’re not a good mother
11. Hopelessness
12. Feelings of worthlessness, shame, guilt or inadequacy
13. Diminished ability to think clearly, concentrate or make decisions
14. Restlessness
15. Severe anxiety and panic attacks
16. Thoughts of harming yourself or your baby
17. Recurrent thoughts of death or suicide

As part of evaluation, doctor may:
• Do a depression screening that may include having fill out a questionnaire

• Order blood tests to determine whether an underactive thyroid is contributing to signs and symptoms

• Order other tests, if warranted, to rule out other causes for the symptoms

There are two main treatments for postpartum depression: medication and therapy. Either one can be used alone, but they may be more effective when used together. It’s also important to make some healthy choices in daily routine.
• Medication: Antidepressants have a direct effect on the brain. They alter the chemicals that regulate mood. They won’t work right away, though. It can take several weeks of taking the medication before the patients notice a difference in mood.
• Therapy: A psychiatrist, psychologist, or other mental health professional can provide counseling. Therapy can help make sense of destructive thoughts and offer strategies for working through them.

Postpartum Depression Emerging Drugs Chapters
This segment of the Postpartum Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postpartum Depression Emerging Drugs
• Zuranolone: Sage Therapeutics
Sage Therapeutics is conducting a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of SAGE-217 in the treatment of adults with severe postpartum depression. The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
Further product details are provided in the report……..

Postpartum Depression: Therapeutic Assessment
This segment of the report provides insights about the different Postpartum Depression drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Postpartum Depression
There are approx. 2+ key companies which are developing the therapies for Postpartum Depression. The companies which have their Postpartum Depression drug candidates in the mid to advanced stage, i.e. phase III include, Sage Therapeutics and others.
This report covers around 2+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Postpartum Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postpartum Depression: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postpartum Depression therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postpartum Depression drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Postpartum Depression R&D. The therapies under development are focused on novel approaches to treat/improve Postpartum Depression.

Postpartum Depression Report Insights
• Postpartum Depression Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Postpartum Depression Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Postpartum Depression drugs?
• How many Postpartum Depression drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postpartum Depression?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Postpartum Depression therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postpartum Depression and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Sage Therapeutics
• Epharmix, Inc.

Key Products
• SAGE-217
• Epharmix

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Uveitis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

  • $ 2299
  • December 2020
  • 146 pages

The global uveitis treatment market grew at a CAGR of around 6% during 2014-2019. Uveitis treatment refers to various therapeutic procedures for treating inflammation in the uvea and surrounding tissues. ...

  • World
  • Therapy
  • Industry analysis


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on